Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Accolade, Inc. - common stock (NQ:ACCD)

7.020 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Accolade, Inc. - common stock

< Previous 1 2 3 4 5 6 7 Next >
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again
The famous growth investor has been making some interesting stock moves lately. 
Via The Motley Fool
Cathie Wood's Bullish Stance on Flying Cars: Ark Buys $3.9M Worth of Archer Aviation Shares
Via Benzinga
Cathie Wood's Ark Invest Adjusts Portfolio — Sells Nvidia Shares Worth Nearly $1.9M Amid AI Surge
Via Benzinga
Topics Artificial Intelligence
Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks
The Ark Invest CEO continues to trim Shopify holdings to fund some big purchases. 
Via The Motley Fool
The Latest Analyst Ratings for Accolade
Via Benzinga
Why Accolade Stock Popped by Almost 7% Today
A double beat and raised guidance bring the bulls roaring back to the stock. 
Via The Motley Fool
Accolade: Q1 Earnings Insights
Via Benzinga
Every AI Stock Cathie Wood Owns, Ranked From Best to Worst
You can find some great AI investment opportunities by looking at the stocks in Wood's Ark Invest portfolio. 
Via The Motley Fool
Topics Artificial Intelligence
Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports
Via Benzinga
Cathie Wood's Ark Invest Acquires $5.5M of Robinhood Shares Following Platform's First Profitable Quarter
Via Benzinga
Cathie Wood Continues Iridium Shopping Spree — Ark Invest Buys $3.6M Worth Of Satellite Company's Stock
Via Benzinga
Earnings Outlook For Accolade
Via Benzinga
What 12 Analyst Ratings Have To Say About Accolade
Via Benzinga
What 12 Analyst Ratings Have To Say About Accolade
Via Benzinga
Downgrade Aside, Cathie Wood Buys $1.2M Worth Of SoFi Shares
Via Benzinga
Cathie Wood's Ark Invest Buys Spotify, Iridium Shares — Trims Tesla, Coinbase Holdings
Via Benzinga
Cathie Wood's Ark Invest Makes Major Moves In This Warren Buffett-Backed EV Company, Moderna
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in... 
Via Benzinga
Accolade's Pipeline Strength Amid Solid Demand To Propel Growth, Bullish Analyst Says
Needham analyst Ryan MacDonald reiterated a Buy rating on the shares of Accolade, Inc. (NASDAQ: ACCD),  
Via Benzinga
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top... 
Via Benzinga
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Analyst Says Accolade's Q1 Earning, Annual Guidance Reflect Solid Performance Amid Uncertain Macroeconomic Environment
Accolade Inc (NASDAQ: ACCD) posted Q1 FY24 sales of $93.2 million, up 9% Y/Y, beating the  
Via Benzinga
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. 
Via Benzinga
NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday
Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today! 
Via InvestorPlace
Shareholders Like What These 2 Companies Just Told Them
Good financial results have investors feeling bullish about their prospects. 
Via The Motley Fool
Accolade's Financial Forecast: Anticipating Raised Guidance and Robust Revenue Growth
Needham analyst Ryan MacDonald reiterated a Buy rating on the shares of Accolade, Inc. (NASDAQ: ACCD) with a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2023
Via Benzinga
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.